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The cysteine protease cathepsin K has been implicated in patho-
genesis of cardiovascular disease. We hypothesized that ablation of
cathepsin K protects against obesity-associated cardiac dysfunc-
tion. Wild-type mice fed a high-fat diet exhibited elevated heart
weight, enlarged cardiomyocytes, increased left ventricular wall
thickness, and decreased fractional shortening. All these changes
were reconciled in cathepsin K knockout mice. Cathepsin K
knockout partly reversed the impaired cardiomyocyte contractility
and dysregulated calcium handling associated with high-fat diet.
Additionally, cathepsin K knockout alleviated whole-body glucose
intolerance and improved insulin-stimulated Akt phosphorylation
in high-fat diet–fed mice. High-fat feeding increased the expression
of cardiac hypertrophic proteins and apoptotic markers, which
were inhibited by cathepsin K knockout. Furthermore, high-fat
feeding resulted in cathepsin K release from lysosomes into the
cytoplasm. In H9c2 myoblasts, silencing of cathepsin K inhibited
palmitic acid–induced release of cytochrome c from mitochondria
and expression of proapoptotic signaling molecules. Collectively,
our data indicate that cathepsin K contributes to the development
of obesity-associated cardiac hypertrophy and may represent a
potential target for the treatment to obesity-associated cardiac
anomalies. Diabetes 62:498–509, 2013
O
besity is an emerging health problem world-
wide and is an independent risk factor for the
pathogenesis of cardiovascular disease (1–3).
Uncorrected obesity predisposes individuals to
myocardial damage characterized as cardiac hypertrophy
and contractile dysfunction (4–6). Although several theories
have been postulated to explain obesity-associated cardiac
anomalies, including alterations in myocardial substrate
utilization, neurohumoral activation, mitochondrial dys-
function, oxidative stress, impaired insulin signaling, and
lipotoxicity, the underlying pathological mechanisms re-
main elusive (7). Obesity is known to trigger a number of
adverse cellular signaling processes in the heart, such as re-
expression of fetal genes, intracellular Ca
2+ mishandling,
derangement in proteins responsible for excitation-
contraction coupling, and cardiac fatty acid oxidation
(8,9). Obesity also triggers changes in extracellular matrix
(10) and apoptosis of cardiomyocytes (11), which also can
contribute to heart failure.
Cathepsins are cysteine proteases that are ubiquitously
expressed in various tissues and are implicated in the
pathogenesis of cardiovascular diseases (12–14). Pri-
marily located in lysosomes, cathepsins are transported
between different cellular organelles and are released
into the circulation under pathological conditions such as
diabetes and atherosclerosis (15,16) or after lysosomal
leakage caused by reactive oxygen species. Once re-
leased from lysosomes, cathepsins trigger apoptotic cell
death by activating caspases and releasing proapoptotic
factors from the mitochondria (17). Elevated levels of
cathepsins S and K have been reported in atherosclerotic
plaques, neointimal lesions, and in the failing heart in
both humans and animals (18–21). Elevated levels of
myocardial cathepsin B has been reported in individuals
with dilated cardiomyopathy (22). However, deﬁciency of
cathepsin L has been associated with cardiomyopathy
whereas overexpression of this protease was shown to
retard cardiac hypertrophy (23), suggesting distinct reg-
ulation of cardiac tissue by various cathepsins. Recent
studies have shown that cathepsin K is elevated in adi-
pose tissues of obese humans and mice and inhibition of
cathepsin K attenuated body weight gain and serum glu-
cose and insulin levels in obese mice (24). Given that
cardiac dysfunction is a major complication of obesity,
this study was designed to test the hypothesis that abla-
tion of cathepsin K protects against high-fat diet–induced
cardiac dysfunction. Our studies reveal that deletion of
cathepsin K attenuates obesity-associated cardiac hy-
pertrophy and contractile dysfunctions.
RESEARCH DESIGN AND METHODS
Experimental animals. The University of Wyoming Institutional Animal Care
and Use Committee approved this study. Six-week-old male cathepsin K
knockout mice (Ctsk
2/2) (25) and wild-type littermates were subjected to
a normal diet (10% calories from fat, 3.91 kcal/g) or high-fat diet (45% calories
from fat, 4.83 kcal/g; Research Diets, New Brunswick, NJ) for 20 weeks. Mice
were housed in a climate-controlled environment (22.8 6 2.0°C, 45–50% hu-
midity) with a 12/12 light/dark cycle with free access to designated diet and
water ad libitum. Body weight and food intake were monitored weekly.
Intraperitoneal glucose tolerance test. After 5 months of high-fat diet, mice
were fasted for 12 h and were challenged with glucose (2 g/kg, in-
traperitoneally). Blood samples were drawn from the tail vein immediately
before glucose challenge, as well as 30, 60, 90, and 120 min thereafter. Serum
glucose levels were determined using a glucometer.
Insulin, triglyceride, cholesterol, and free fatty acid detection. Serum
insulin levels were detected by enzyme-linked immunosorbent assay (Milli-
pore). Serum triglyceride, cholesterol, and free fatty acid and cardiac and liver
triglycerides were detected by kits from BioVision (Milpitas, CA).
Echocardiographic analysis. Cardiac geometry and function were evaluated
in anesthetized mice using a two-dimensional guided M-mode echocardiog-
raphy (Sonos 5500; Phillips Medical System, Andover, MA) equipped with a 15–
6 MHz linear transducer as reported previously (26). Anterior and posterior
wall thicknesses and diastolic and systolic left ventricular dimensions were
recorded from M-mode images. Left ventricular fractional shortening was
calculated from left ventricular end diastolic diameter (LVEDD) and left
ventricular end systolic diameter (LVESD) using the following formula:
(LVEDD 2 LVESD) / LVEDD 3 100.
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ORIGINAL ARTICLEBlood pressure measurement. Mouse systolic and diastolic blood pressures
were measured by a CODA semiautomated noninvasive blood pressure device
(Kent Scientiﬁc, Torrington, CT).
Cardiomyocyte isolation and mechanics. Mouse cardiomyocytes were
isolated using liberase enzymatic digestion; mechanical properties were
assessed using an IonOptix soft-edge system (IonOptix, Milton, MA) as de-
scribed previously (27). For experiments involving the inhibition of cathepsin
K, isolated cardiomyocyte from high-fat diet–fed wild-type mice were in-
cubated for 2 h with various concentration of cathepsin K inhibitor II (Cal-
biochem). Cell shortening and relengthening were assessed using peak
shortening (PS), time to PS, time to 90% relengthening, and maximal velocities
of shortening/relengthening (6dL/dt).
Intracellular Ca
2+ transients. A cohort of myocytes was loaded with fura-2/
AM (0.5 mmol/L) for 15 min, and ﬂuorescence intensity was recorded with
a dual-excitation ﬂuorescence photomultiplier system (IonOptix). Cells were
exposed to light emitted by a 75-W lamp while being stimulated to contract at
a frequency of 0.5 Hz. Fluorescence emissions were detected between 480 and
520 nm; qualitative change in fura-2 ﬂuorescence intensity was inferred from
the fura-2 ﬂuorescence intensity ratio at the two wavelengths (360/380).
Fluorescence decay rate was calculated as an indicator of intracellular Ca
2+
clearing (27).
Histopathological analysis and TUNEL staining. Ventricular tissues were
stained with FITC-conjugated wheat germ agglutinin and cardiomyocyte cross-
sectional area was quantitated by measuring 60 random cardiomyocytes. Fi-
brotic area was measured on Masson trichrome-stained sections. Apoptotic
cardiomyocytes were detected by using the In Situ Death Detection Kit (Roche,
Branchburg, NJ), with myocytes counterstained by Desmin antibody (Cell
Signaling Technology, Beverly, MA) and observed using a Zeiss confocal mi-
croscope. Adipose tissues were stained with hematoxylin and eosin; adipocyte
sizes were quantitated by measuring 60 random adipocytes.
Assessment of mRNA expression by quantitative real-time PCR. Total
RNA was isolated from left ventricles followed by DNase digestion to elim-
inate genomic DNA contamination. Synthesis of cDNA was performed at 37°C
for 60 min using 1 mg total RNA in a 20-mL system by Superscript III.
Quantitative real-time RT-PCR analysis was performed for cathepsins B, D,
H, K, and L, cystatin-C, fatty acid transport protein-1, muscle carnitine pal-
mitoyl transferase-1, long-chain acyl CoA dehydrogenase, CD36, succinyl-
CoA:3-ketoacid CoA transferase, acetyl-coA carboxylase-a, peroxisome
proliferator–activated receptor-a, and 18S (housekeeping gene). The primer
sequences are shown in Supplementary Table 1.
Western blot analysis. Protein was extracted using a RIPA lysis buffer and
Western blotted against antibodies for GATA binding protein-4 (GATA4),
NFATc3, atrial natriuretic peptide (ANP), cathepsins B, K, L, and S, phos-
pholamban, phospho-phospholamban, sarcoplasmic/endoplasmic reticulum
Ca
2+-ATPase-2 (SERCA2), phospho-Akt, Akt, insulin receptor-b, cytochrome
C, BAX, cleaved caspase-3, BCL-XL, cleaved nuclear enzyme poly (ADP-
ribose) polymerase (PARP), catD, glucose transporter-4, COXIV (used as the
loading control for mitochondrial proteins), and GAPDH (loading control)
(27).
RNA silencing. H9c2 myoblasts were grown up to 80% conﬂuence, and small
interfering RNAs (siRNAs) of cathepsin K (25 nmol/L) or control nontarget
siRNA were transfected using DharmaFECT transfection reagent per manu-
facturer’s instructions.
Cell viability. H9c2 myoblast viability was assessed after treatment with
palmitic acid (0.4 mmol/L, 6 h) by measuring formazan. Palmitate-containing
media was prepared by conjugating palmitic acid with fatty acid–free bovine
serum albumin (28).
Lysosome and cathepsin K staining. Lysosomes were stained with Cell
Navigator lysosomal staining kit (ATT Bioquest, Sunnyvale, CA). Intracellular
cathepsin K was detected by Magic Red-cathepsin K reagent staining
(ImmunoChemistry Technologies, Bloomington, MN).
Statistical analysis. Data are presented as mean 6 SEM. Statistical com-
parison was performed by the two-way ANOVA followed by a Bonferroni post
hoc test using the SigmaPlot software (Jandel Scientiﬁc, San Rafael, CA) for
comparison of multiple groups. The Student t test was used to compare two
groups. The null hypothesis was rejected with P , 0.05.
RESULTS
Increased expression of cathepsin K in the heart
after high-fat feeding. As illustrated in Supplementary
Fig. 1A and B, cardiac protein levels of cathepsins K and B
were signiﬁcantly elevated in mice fed the high-fat diet
compared with the normal diet (Supplementary Fig. 1A
and B), whereas other cathepsins remained unaltered
(cathepsins S and L are shown). In contrast, the high-fat
diet did not alter the message levels of any cathepsins or
cystatin C (the endogenous inhibitor of cathepsin) (Sup-
plementary Fig. 1C). To determine the cellular source of
cathepsin K, we performed immunohistochemical analysis
on isolated cardiomyocytes. Supplementary Fig. 1D and E
demonstrate that high-fat diet feeding resulted in increased
cathepsin K–positive staining (puncta) in the cardiomyocytes.
The extralysosomal cathepsin K–positive puncta indicate
that high-fat feeding results in cathepsin K release from
lysosomes to the cytoplasm.
Cathepsin K knockout does not affect high-fat diet–
induced changes in body lipid content. High-fat diet
feeding resulted in a signiﬁcant elevation in serum
triglycerides, cholesterol, and free fatty acids, as well as
cardiac and liver triglyceride levels (Table 1). None of
these parameters were altered by cathepsin K knockout.
Cathepsin K knockout does not alter blood pressure.
The systolic and mean blood pressures were unchanged
after high-fat diet feeding in the wild-type and cathepsin K
knockout mice, nor did the high-fat diet per se increase
diastolic blood pressure. A slightly lower diastolic blood
pressure was recorded in cathepsin K knockout mice fed
the normal diet. Furthermore, cathepsin K knockout mice
on a high-fat diet exhibited a comparable diastolic blood
pressure with that of the wild-type mice fed a high-fat diet
(Supplementary Fig. 2).
Cathepsin K knockout alleviates high-fat diet–induced
glucose intolerance. In wild-type mice fed the normal
diet, after acute glucose challenge serum glucose peaked
at 30 min and approached baseline after 120 min (Fig. 1A
and B). In contrast, postchallenge glucose levels remained
at much higher levels between 30 and 120 min in high-fat
diet–fed wild-type mice, indicating glucose intolerance. In
high-fat diet–fed cathepsin K knockout mice, postchal-
lenge blood glucose peaked at 30 min (similar to high-fat
diet–fed wild types), but glucose levels were signiﬁcantly
lower at 60, 90, and 120 min. However, the total area under
the glucose disposal curve did not show a signiﬁcant effect
of cathepsin K knockout in the integrated postglucose
challenge glucose disposal (Fig. 1B). In addition serum
glucose and insulin levels that were signiﬁcantly elevated in
the high-fat diet–fed mice were attenuated in the cathepsin
K knockout mice (Table 1).
Cathepsin K knockout attenuates weight gain and
cardiac hypertrophy in response to high-fat diet
feeding. Whereas food intake did not differ by cathepsin
knockout or diet, wild-type mice fed the high-fat diet
gained signiﬁcantly more weight than those fed the normal
diet (Table 1 and Fig. 1C). High-fat feeding also resulted in
a signiﬁcant increase in organ weight (heart and liver, but
not kidneys) compared with normal diet-fed mice (Table 1,
Fig. 1B). Cathepsin K knockout and wild-type mice fed
a normal diet did not differ in body or organ weight gain.
Although cathepsin K knockout mice also gained weight
after high-fat diet feeding, the weight gain was signiﬁcantly
less than that of wild-type mice. However, the high-fat diet–
induced accumulation of epididymal fat and adipocyte hy-
pertrophy was unaltered in the cathepsin K knockout mice
(Table 1, Supplementary Fig. 3, respectively).
In high-fat diet–fed cathepsin K knockout mice, heart
weight and heart weight to tibia length were signiﬁcantly
reduced compared with high-fat diet–fed wild-type mice
and did not differ signiﬁcantly from the mice fed a normal
diet (Table 1). Histological analysis revealed that the heart
size and cardiomyocyte cross-sectional area were signiﬁ-
cantly increased in high-fat diet–fed wild-type mice,
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Similarly, markers of hypertrophy (NFATc3, GATA4, and
ANP) were signiﬁcantly upregulated after high-fat diet,
changes that are attenuated in cathepsin K knockouts
(Fig. 1G and Supplementary Fig. 4). Additionally, car-
diomyocytes isolated from high-fat diet–fed cathepsin K
knockout mice were signiﬁcantly smaller compared with
those obtained from the high-fat diet–fed wild-type mice
(Fig. 1H), supporting the notion that the observed increase
in heart mass is attributable to myocyte hypertrophy, not
increased interstitial content. The high-fat diet increased
the extent of interstitial ﬁbrosis, but cathepsin K knockout
did not lower the extent of ﬁbrosis (Supplementary Fig. 5).
Cathepsin K knockout ameliorates obesity-induced
compromised cardiac performance. Baseline heart rates
did not differ between genotypes or diet groups (Table 1).
High-fat feeding led to compromised echocardiographic
function, as evidenced by a signiﬁcant increase in left
ventricular wall thickness without affecting the diameters
(LVEDD and LVESD), indicating a concentric pattern of
cardiac hypertrophy (Fig. 2A–C). In addition, high-fat diet
feeding elicited a signiﬁcant decrease in fractional short-
ening. Cathepsin K knockout ameliorated the high-fat diet–
induced wall thickening and impaired fraction shortening
but, by itself, did not affect myocardial geometry or frac-
tion shortening (Fig. 2D).
Cathepsin K knockout reconciles high-fat diet–induced
impaired cardiac contractility and intracellular Ca
2+
handling. To further evaluate the effects of cathepsin K
knockout on cardiac function, we assessed contractile
function and intracellular Ca
2+ handling in isolated car-
diomyocytes (see Fig. 4). Neither high-fat diet nor cathepsin
K ablation affected resting cell length (Fig. 3C). In wild-type
mice, high-fat intake signiﬁcantly reduced PS, reduced
maximum velocity of shortening/relengthening (6dL/dt),
and prolonged time to 90% relengthening without affecting
time to PS (Fig. 3D–H). Strikingly, cathepsin K knockout
rescued these high-fat diet–induced cardiomyocyte mechan-
ical anomalies in PS, 6dL/dt, and time to 90% relengthening.
Intracellular calcium changes associated with the high-fat
diet were nulliﬁed in cathepsin K knockouts. Cardiomyocytes
from high-fat diet–fed wild-type mice displayed signiﬁcantly
elevated baseline intracellular Ca
2+ and peak intracellular
Ca
2+ levels, reduced intracellular Ca
2+ increase in re-
sponse to electrical stimulus (Dfura-2 ﬂuorescence in-
tensity), and delayed intracellular Ca
2+ clearance (Fig. 4A–D).
Interestingly, however, cathepsin K knockout mice that
received a normal diet also exhibited elevated baseline and
peak intracellular Ca
2+. Figure 4E to 4H illustrates that
cardiac expression of the Ca
2+-handling proteins SER-
CA2a and phospholamban are both enhanced in the high-
fat diet–fed mice, although the levels of phosphorylated
phospholamban and the ratio of SERCA2a to phospho-
lamban remained unaltered. In contrast, SERCA2a, phos-
pholamban, and phospholamban-to-SERCA2a ratio were
all elevated in cathepsin K knockout mice under basal
conditions, suggesting a phenotypic difference in terms
of Ca
2+-handling proteins. Consistent with our results from
the cathepsin K knockout mice, pharmacological in-
hibition of cathepsin K partially reconciled the impaired
contractile parameters in cardiomyocytes from high-fat
diet–fed mice (Fig. 5).
Cathepsin K knockout does not alter genes involved
in cardiac fatty acid metabolism. Because the cardiac
substrate utilization is known to switch from pre-
dominantly oxidation of fatty acids to carbohydrate me-
tabolism in response to nutritional stress, we evaluated the
effect of cathepsin K knockout on the expression of genes
involved in fatty metabolism. Wild-type mice subjected to
high-fat diet exhibited decreased expression of genes as-
sociated with cardiac fatty acid utilization and transport
(fatty acid transport protein1, acetyl-coA carboxylase-a,
and peroxisome proliferator–activated receptor-a) com-
pared with those that received a normal diet; this was not
observed in the cathepsin K knockout mice. No changes
were observed in the message levels of fatty acid transport
protein-4, muscle carnitine palmitoyl transferase-1, long-
chain acyl CoA dehydrogenase, CD36, and succinyl-CoA:
3-ketoacid CoA transferase levels among any of the treat-
ment groups (Supplementary Fig. 6).
Cathepsin K deﬁciency inhibits cardiomyocyte apoptosis.
Consistent with previous reports (11,29), chronic high-fat
feeding caused a signiﬁcant elevation in cardiomyocyte
apoptosis as evidenced by increased TUNEL-positive nu-
clei (Fig. 6A and B) and increased expression of proa-
poptotic proteins cytochrome C, BAX, cleaved caspase-3,
TABLE 1
General features of wild-type and cathepsin K knockout mice after 20 weeks of a normal diet or a high-fat diet
Parameter WT-ND WT-HFD Ctsk
2/2-ND Ctsk
2/2-HFD
Food intake, g/mouse/day 3.60 6 0.03 3.60 6 0.03 3.57 6 0.01 3.55 6 0.01
Body weight, g 30.20 6 0.29 53.32 6 0.77* 30.98 6 0.87 44.05 6 1.81†‡
Epididymal fat pad, g 0.378 6 0.06 2.069 6 0.99* 0.581 6 0.95 2.497 6 0.16†
Heart weight, mg 167 6 7 214 6 10* 165 6 10 154 6 4‡
Liver weight, g 1.57 6 0.1 2.79 6 0.2* 1.56 6 0.1 1.67 6 0.2‡
Kidney weight, g 0.41 6 0.02 0.47 6 0.02 0.42 6 0.01 0.43 6 0.03
Tibia length, mm 20.98 6 0.68 20.67 6 0.96 22.7 6 0.2 22.7 6 0.18
Heart weight/tibia length, mg/mm 7.99 6 0.41 10.53 6 0.75* 7.27 6 0.49 6.77 6 0.17‡
Heart rate, bpm 496 6 31 458 6 21 472 6 34 414 6 48
Plasma insulin, ng/mL 0.20 6 0.08 2.64 6 0.19* 0.31 6 0.07 0.67 6 0.04†‡
Plasma glucose, ng/mL 71.57 6 2.7 118.75 6 12.4* 74.20 6 4.3 89.40 6 10.76
Serum triglyceride, nmol 0.94 6 0.05 1.36 6 0.03* 0.75 6 0.09 1.22 6 0.04†
Serum cholesterol, mg 0.49 6 0.13 2.03 6 0.26* 0.38 6 0.05 1.88 6 0.08†
Serum free fatty acid, nmol 0.27 6 0.05 0.61 6 0.07* 0.29 6 0.05 0.46 6 0.04†
Cardiac triglyceride, nmol 0.40 6 0.09 1.89 6 0.19* 0.40 6 0.05 2.12 6 0.40†
Liver triglyceride, nmol 0.48 6 0.09 6.23 6 0.55* 0.56 6 0.11 6.55 6 0.91†
Values are mean 6 SEM, n =6 –7 mice per group. WT, wild-type; ND, normal diet; HFD, high-fat diet. *P , 0.05 vs. WT-ND group. †P , 0.05 vs.
Ctsk
2/2 -ND. ‡P , 0.05 vs. WT-HFD.
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antiapoptotic BCL-XL (Fig. 6C, quantiﬁcation of the blots
provided in Supplementary Fig. 7), which was reconciled
by cathepsin K knockout. Additionally, rat cardiac H9c2
cells transfected with cathepsin K siRNA exhibited reduced
levels of apoptotic protein expression when challenged with
the saturated fatty acid, palmitic acid (Fig. 6D and Supple-
mentary Fig. 8A). Apoptosis induced by palmitic acid was
characterized by a signiﬁcant increase in cytosolic cyto-
chrome C with a reciprocal reduction of the mitochondrial
cytochrome C (Fig. 6D and Supplementary Fig. 8B–D).
Cathepsin K silencing attenuated palmitic acid–induced
FIG. 1. A and B: Effect of cathepsin K knockout on glucose disposal in mice fed a normal diet (ND) or a high-fat diet (HFD) after an intraperitoneal
glucose (2 g/kg, body weight) challenge (A). Integrated area under the postglucose challenge, glucose-disposal curve (B). C: Effect of ND and HFD,
respectively, on body weight gain over a 20-week period in wild-type and cathepsin K knockout mice. D: Representative images of wild-type (WT)
and cathepsin K knockout mice fed ND or HFD and representative hearts from each group. E–H: Effect of cathepsin K knockout on HFD-induced
cardiac hypertrophy. Representative images using wheat germ agglutinin staining of the left ventricular tissue (E), quantitation of cardiomyocyte
cross-sectional area (F), and representative gel blots for GATA4, NFATc3, ANP, and GAPDH (loading control) (G), and size of isolated car-
diomyocytes (H). Data are represented as mean 6 SEM, n =5 –7 mice per group, *P < 0.05 between the notated groups. (A high-quality color
representation of this ﬁgure is available in the online issue.)
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of H9C2 cells for cathepsin K and lysosomes demonstrated
that cathepsin K is predominantly localized in the lyso-
somes under basal condition (Fig. 7A). On stimulation with
palmitic acid, cathepsin K staining was observed in the
cytoplasm as well, suggesting that palmitic acid challenge
causes the release of cathepsin K from the lysosomes into
the cytoplasm (Fig. 7A).
Cathepsin K knockout alleviates cardiac insulin
resistance. Because whole-body glucose disposal was fa-
cilitated in cathepsin K knockout, we investigated the effect of
high-fat diet feeding and cathepsin K knockout on key
proteins in insulin signaling pathways. We transiently chal-
lenged the mice with insulin before removing the heart.
Hearts from high-fat diet–fed wild-type mice demon-
strated a signiﬁcant blunting of insulin-stimulated Akt-
phosphorylation; this was reversed in cathepsin K knockout
mice (Fig. 7). In contrast, basal levels (without insulin in-
jection) of phospho-Akt and insulin receptor-b were ele-
vated in hearts from high-fat diet–fed wild-type mice hearts
compared with those fed the normal diet; this was attenu-
ated by cathepsin K knockout (Fig. 7B,D,E).
High-fat diet feeding results in compensatory
upregulation of cathepsin L in cathepsin K knockout
mice. We determined if ablation of cathepsin K causes a
compensatory upregulation of other cathepsins in hearts
from normal diet-fed and high-fat diet–fed mice. Al-
though cathepsin K knockout per se did not result in the
upregulation of other cathepsins, a signiﬁcant upregu-
lation of cathepsin L was seen in the hearts of cathepsin
K knockout mice subjected to high-fat diet feeding (Fig.
7F and G).
DISCUSSION
Several studies have consolidated the role of obesity as an
independent risk for cardiac hypertrophy and contractile
dysfunction. In this study, we examined the role of ca-
thepsin K in obesity-induced cardiac morphometric and
functional changes. Our data indicated that cathepsin K
was upregulated in the myocardium in response to high-fat
diet feeding and cathepsin K deletion effectively attenu-
ated or mitigated high-fat diet–induced cardiac hyper-
trophy, contractile dysfunctions, and intracellular Ca
2+
derangements. High-fat diet–induced cardiac geometric
and functional anomalies were associated with the in-
creased cardiac expression of prohypertrophic proteins
GATA4, NFATc, and ANP, as well as elevated levels of
apoptosis, all of which were negated by cathepsin K de-
letion. Furthermore, ablation of cathepsin K resulted in
reduced high-fat diet–induced body weight gain and im-
proved whole-body glucose disposal subsequent to a glu-
cose challenge. Additionally, the cathepsin K knockout
attenuated the elevated serum insulin and glucose levels
and blunted cardiac insulin signaling associated with high
fat. In cultured cardiac myoblasts palmitic acid (a satu-
rated fatty acid and an essential component of the high-fat
diet) upregulated cathepsin K, stimulated cathepsin K re-
lease from lysosomes into the cytoplasm, and induced
apoptosis. These untoward effects of palmitic acid were
inhibited by cathepsin K silencing. Collectively, these
data show that cathepsin K ablation mitigates obesity-
associated cardiac dysfunctions, and these effects may be
mediated by the attenuation of high-fat diet–induced
weight gain, alleviation of insulin resistance, and inhibition
of apoptosis.
FIG. 2. Echocardiographic features in wild-type (WT) and cathepsin K knockout mice fed normal diet or high-fat diet. A: Left ventricular wall
thickness. B:L V E D D .C:L V E S D .D: Fraction shortening [(LVEDD 2 LVESD) / LVEDD 3 100]. Mean 6 SEM, n =6 –7 mice per group, *P < 0.05 between
the notated groups.
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levels of cathepsins in the failing heart, which has been
recently reviewed by Cheng et al. (14). Whereas elevated
levels of myocardial cathepsins K and S have been
reported in cardiac hypertrophy and heart failure in both rats
and humans (21), overexpressing cathepsin L has been
shown to improve cardiac function via retarding cardiac
hypertrophy (23). In our studies, protein levels of cathep-
sins K and B were upregulated in the hearts after high-fat
diet, without signiﬁcant alterations in other cathepsins.
FIG. 3. Cardiomyocyte contractile properties in wild-type (WT) and cathepsin K knockout mice fed normal diet (ND) or high-fat diet (HFD). A and
B: Representative traces from cardiomyocytes isolated from wild-type and cathepsin K knockout mice. C–H: Resting cell length, peak shortening
(normalized to cell length), maximal velocity of shortening (+dL/dt), maximal velocity of relengthening (2dL/dt), time-to-peak shortening (TPS),
and time to 90% relengthening (TR90), respectively. Mean 6 SEM, n =7 6 –87 cells per group. *P < 0.05 between the notated groups.
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2+ transients in cardiomyocytes and expression levels of proteins related to intracellular Ca
2+ handling in wild-type (WT)
and cathepsin K knockout mice fed a normal diet (ND) or high-fat diet (HFD). A–D: Resting fura-2 ﬂuorescence intensity (FFI), electrically
stimulated increase in FFI (DFFI), single exponential intracellular Ca
2+ decay, and peak FFI, respectively. E: Representative Western blot images
for phospho-phospholamban, phospholamban (PLB), SERCA2, and GAPDH (loading control). F–H: Densitometric quantitation of SERCA nor-
malized to GAPDH, PLB normalized to GAPDH, and PBL-to-SERCA ratio, respectively. Mean 6 SEM, n =9 4 –100 cells or 5–7 mice per group.
*P < 0.05 between the notated groups.
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levels of these proteins is consistent with the observations
made by previous studies that cathepsin K expression is
regulated at the translation level (18). Although knock-
down of the cathepsin K gene did not alter the expression
of other cathepsins at basal levels, high-fat diet feeding
resulted in an induction of cathepsin L in the cathepsin K
knockout mice, suggesting a compensatory effect. This is
signiﬁcant because cathepsin L has been shown to coun-
teract cardiac dysfunctions (30,31), thus suggesting a re-
ciprocal regulation of cardiac structure and function by
these cathepsins.
Yang et al. (24) found a reduction in weight gain and
body fat accumulation in female cathepsin K knockout
mice subjected to high-fat diet. Consistent with these
ﬁndings, cathepsin K ablation attenuated body weight gain
in our studies. However, we did not see any changes in fat
accumulation consequent to cathepsin K knockout. This
discrepancy may be attributed to gender differences be-
cause we used only male mice in our study. Neither
message levels of the transcription factors involved in fatty
acid transport and utilization nor serum lipid levels pro-
vided an explanation of the beneﬁts of cathepsin K
knockout, because these parameters, although altered by
high-fat diet, were not affected by knockout of cathepsin
K. Lower levels of peroxisome proliferator–activated
receptor-a and acetyl-coA carboxylase-a in the knockout
mice compared with wild-type mice under high-fat diet
conditions indicate improved fatty acid utilization in ca-
thepsin K knockout mice, which, however, fails to explain
its lack of effect on fat accumulation.
Numerous studies have shown that high-fat diets worsen
cardiac remodeling and cause contractile dysfunction (32).
In the current study, we found the high-fat diet was asso-
ciated with impaired cardiomyocyte contractility and in-
tracellular Ca
2+ handling, which were reconciled by
cathepsin K knockout. Additionally, pharmacological in-
hibition of cathepsin K reversed palmitic acid–induced
impaired cardiomyocyte contractility, suggesting a direct
role of cathepsin K in regulating cardiac contractility.
FIG. 5. Effect of cathepsin K inhibitor II on resting cell length (A), PS (B), and time to 90% relengthening (C) of cardiomyocytes isolated from
normal diet (ND)-fed and high-fat diet (HFD)-fed wild-type mice. Data are means 6 SEM, n = 50 cardiomyocytes per group. *P < 0.05 vs. ND control
group, #P < 0.05 vs. HFD control group.
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diabetes.diabetesjournals.org DIABETES, VOL. 62, FEBRUARY 2013 505FIG. 6. A and B: Representative TUNEL staining of cardiomyocytes from heart sections of wild-type (WT) mice fed a high-fat diet (HFD). Apoptotic
nuclei stained by TUNEL (green), counterstained with DAPI (blue) to mark nuclei, and cardiomyocytes (desmin, red) were imaged by confocal
microscopy, arrow indicates TUNEL-positive nuclei in the cardiomyocyte (A); and quantitation of TUNEL-positive cardiomyocytes (B). ND, normal
diet. *P < 0.05 between the notated groups. C: Effect of cathepsin K knockout on HFD-induced cardiac apoptosis. Representative Western blot
image of proapoptotic proteins cytochrome C, BAX, cleaved caspase-3, cleaved nuclear enzyme poly (ADP-ribose) polymerase (PARP), and the
antiapoptotic protein BCL-XL are shown. D: H9c2 myoblasts were transfected with nontarget siRNA (NT-siRNA) or cathepsin K siRNA in the
presence of palmitic acid (0.4 mmol/L, 6 h) or vehicle BSA. Representative gel blots of total cathepsin K, mitochondrial cytochrome C, mito-
chondrial PARP, COXIV (loading control), and cytosolic cytochrome C, cytosolic PARP, and GAPDH (loading control). (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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hypertrophy (33), whereas an increase in its inhibitory
subunit phospholamban (nonphosphorylated, monomeric)
induces hypertrophy (34). Contrary to this notion, we found
an upregulation of SERCA2a and phospholamban after
high-fat feeding. More importantly, cathepsin K knockout
resulted in elevated SERCA2a and phospholamban and the
ratio of phospholamban to SERCA2a. Although the signiﬁ-
cance of these ﬁndings are difﬁcult to explain in the context
of improved contractility, the elevated phospholamban-
to-SERCA2a ratio may partly explain the increased resting
Ca
2+ in the myocytes from cathepsin K knockout mice.
FIG. 7. A: Immunolocalization of cathepsin K in cultured cells. H9c2 myoblasts were labeled using lysosomal dye and ﬂuorogenic substrate MR-
(LR)2, which detects active cathepsin K. Upper panel (merged ﬁgure) shows colocalization of cathepsin K in lysosomes under basal conditions. On
stimulation with palmitic acid, active cathepsin K was released from lysosomes to the cytoplasm (indicated by arrows). B–E. Effect of cathepsin K
knockout on cardiac insulin signaling molecules in normal diet (ND)-fed and high-fat diet (HFD)-fed mice. Mice were challenged with insulin (1.5
U/100 g body weight, intraperitoneally) for 10 min before isolation of the heart tissue for Western blot. Insulin-stimulated phosphorylation of Akt
(indicated by an asterisk), total Akt, basal phospho-Akt, basal levels of insulin receptor-b, and glucose transporter-4 (Glut4) were assessed by
Western blotting (B) and quantitated by densitometry (C–E). F and G: Effect of cathepsin K knockout on the protein levels of other cathepsins in
ND-fed and HFD-fed mice. Mean 6 SEM, n =3 –4 per group. WT, wild-type. *P < 0.05 between the notated groups. (A high-quality digital repre-
sentation of this ﬁgure is available in the online issue.)
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K knockout attenuates high-fat diet–induced cardiac hyper-
trophy. Previous studies have shown that inhibition of pro-
teases such as the matrix metalloproteinases ameliorates
myocardial remodeling by inhibiting both cardiomyocyte
hypertrophy and interstitial ﬁbrosis (35). In contrast, cardiac
ﬁbrosis was unaltered by cathepsin K knockout, suggesting
that attenuation of heart weight was a consequence of
reduction in individual myocyte size. This was further
conﬁrmed by comparing the size of the individual car-
diomyocytes isolated from high-fat diet–fed wild-type and
cathepsin K knockout mice. Akt has pleotropic effects on
the heart (36); short-term activation of Akt in the heart can
cause physiological hypertrophy (37), whereas sustained
activation of Akt can result in pathological hypertrophy
(38). Activation of fetal genes ANP, GATA4, and NFATc3
suggests pathological hypertrophy in our high-fat diet–fed
mice. Some of the beneﬁcial effects of cathepsin K
knockout on cardiac hypertrophy may be attributed to its
ability to alleviate insulin resistance, as evidenced by in-
hibition of high-fat diet–induced elevated cardiac phospho-
Akt and insulin receptor-b, reversal of the blunting of cardiac
insulin-stimulated Akt phosphorylation, and increased in-
sulin-stimulated Akt phosphorylation and improved serum
glucose and insulin levels.
Cardiac hypertrophy is an adaptive response to a variety
of intrinsic and extrinsic stimuli. Paradoxically, myocyte
apoptosis plays a critical role in causing cardiac hyper-
trophy and heart disease (39,40). Because myocytes are
nondividing cells, apoptosis of cardiomyocytes causes the
workload on the remaining cardiomyocytes to increase,
eventually leading to hypertrophy. Recent studies have
implicated cathepsins in the regulation of apoptosis
(17,41). Our studies demonstrate that a high-fat diet
induces cardiomyocyte apoptosis that is nulliﬁed by ca-
thepsin K ablation. Furthermore, silencing of cathepsin K
inhibited apoptotic responses to palmitic acid, and
pharmacological inhibition of cathepsin K abrogated
apoptotic response to staurosporine (data not shown).
The beneﬁts of cathepsin K inhibition may be partly
mediated by blocking the proapoptotic actions of ca-
thepsin K.
In summary, our ﬁnding that cathepsin K ablation inhibits
obesity-associated cardiac hypertrophy and contractile
dysfunction without affecting basal cardiac function pro-
vides a novel target for intervention in obesity-associated
heart disease. Given that selective pharmacological inhib-
itors of cathepsin K are being designed for clinical use in the
treatment of osteoporosis and other diseases, the role of
cathepsin K in cardiac dysfunction may assume new sig-
niﬁcance.
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